we have run a tight ship - I think the recent SP tune up or...

we have run a tight ship - I think the recent SP tune up or stepping up has been the markets general understanding we are reaching news on a few fronts.

james and team have been very good at depressing the leaks for shorter term holders for us long term supporters... ultimately they suck profits from us along the way.

many discredited the amount of work over the last 5-6 years to not only open all these trials opportunities and relationships but also to get this vehicle ’racing ready’ I think we are in a very good place to really rip with the right combination of news events

And I agree with our US brothers - I hope more find the fortitude to hold but doing nothing is very difficult for some.

last year was a great year for SP increase - this year should be better in terms of percentage of increase - we are ready for it.



—-

in an unrelated topic I watched the more recent NOX interviews and I noticed that Mr Kelly has fundamentally changed his approach - as longer term holders will remember he was always of a mind to own the complete discovery to approval, marketing production and supply chain... even if compound production was outsourced he wanted full control and this has changed he’s now looking to larger partners to fund phase 3 and commercialise... this will sound familiar to us.

James Garner has been a game changer here - his experience in large pharma (specifically Sanofi for me) and realisation of where the opportunities lie has been greatly beneficial for us. And it’s due to his involvement we are adopting new agile techniques and realising the strategic value adding opportunities that arise at critical injunctions in these process’ spanning years and also he knew that partnered trials are not a loss of control but a massive widening of opportunities of study and massive massive cost reductions... this has been our super power IMHO.

And what came with this paradigm shift in management is of course the excellent choice of GDC0084 - Paxalisib and all it offers in the growing PI3K ecosystem but specifically across multiple brain cancer and other brain conditions treatments... we would be hanging our hat on Cantrixil alone if things had been different

which leads to this point we have an astute board in recognising James Garner who is clearly radically different to Mr Kelly - but it seems Mr Kelly is adopting this approach to NOX - which is great to see as well.